An investigation of methadone-related mortalities: A report from southeast of Iran

Kasra Madani; Motahareh Soltani; Fateme Bagheri; Somayyeh Karami-Mohajeri; Omid Mehrpour; Zohreh Oghabian

doi:10.5055/jom.0897

Authors

Kasra Madani, MD
Motahareh Soltani, PhD
Fateme Bagheri, MD
Somayyeh Karami-Mohajeri, PhD
Omid Mehrpour, MD, FACMT
Zohreh Oghabian, MD

DOI:

https://doi.org/10.5055/jom.0897

Keywords:

methadone, poisoning, mortality, Kerman, Iran

Abstract

Background: Methadone is increasingly being used as a pharmacological agent in treating opioid use disorder (OUD). However, reports of illicit overuse of methadone have resulted in fatal consequences, mainly in those under methadone maintenance treatment (MMT). Considering the high prevalence of opioid addiction in Kerman, the present study was conducted to investigate methadone-related deaths in this province.

Methods: A descriptive cross-sectional study was performed on mortality cases caused by methadone use referred to the Forensic Medicine Organization of the Kerman Province in 2020 and 2021. The demographic data as well as concurrent abused substances were extracted from records.

Results: A total of 370 methadone-related deaths were registered, of which 45.7 percent were related to 2020, and 54.3 percent were related to 2021. Most cases had been referred to Kerman (65.9 percent), Sirjan (16.8 percent), Rafsanjan (6.2 percent), and Zarand (3.2 percent) forensic medicine centers. Of the deceased, 75.9 percent were men. The average age of the deceased was 33.37 ± 12.83 years, ranging from 6 days to 72 years. The majority of the cases had low levels of education. In 4.1 percent of the cases, simultaneous use of methadone and tramadol was reported, while 7.6 percent of the cases had simultaneous use of stimulants/hallucinogens, and 3.6 percent had simultaneous use of alcohol.

Conclusion: Taken together, considering the high frequency of methadone-related deaths in the Kerman Province as well as the low level of socio-economic status in the deceased, designing interventions to enhance the awareness of addicts, especially those who are undergoing MMT programs, could potentially reduce the incidence of methadone poisoning.

Author Biographies

Kasra Madani, MD

Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran

Motahareh Soltani, PhD

Pistachio Safety Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran

Fateme Bagheri, MD

Legal Medicine Research Center, Legal Medicine Organization, Kerman, Iran

Somayyeh Karami-Mohajeri, PhD

Neuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran

Omid Mehrpour, MD, FACMT

Michigan Poison & Drug Information Center, School of Medicine, Wayne State University, Detroit, Michigan

Zohreh Oghabian, MD

Fellowship, Gastroenterology and Hepatology Research Center, Kerman University of Medical Sciences, Kerman, Iran. Corresponding author: zoghabian@yahoo.com

References

Ghoreishi SMS, Shahbazi F, Mirtorabi SD, et al.: Epidemiological study of mortality rate from alcohol and illicit drug abuse in Iran. J Res Health Sci. 2017; 17(4): 395.

Vos T, Abajobir AA, Abate KH, et al.: Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: A systematic analysis for the global burden of disease study 2016. Lancet. 2017; 390(10100): 1211-1259.

Degenhardt L, Peacock A, Colledge S, et al.: Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: A multistage systematic review. Lancet Global Health. 2017; 5(12): e1192-e207.

Alinejad S, Zamani N, Abdollahi M, et al.: A narrative review of acute adult poisoning in Iran. Iran J Med Sci. 2017; 42(4): 327.

Strang J, Volkow ND, Degenhardt L, et al.: Opioid use disorder. Nat Rev Dis Primers. 2020; 6(1): 3.

Hassanian-Moghaddam H, Zamani N: An overview on methadone-intoxicated patients. Neuropathol Drug Addict Subst Misuse. 2016; 3: 525-531.

Zamani S, Farnia M, Tavakoli S, et al.: A qualitative inquiry into methadone maintenance treatment for opioid-dependent prisoners in Tehran, Iran. Int J Drug Policy. 2010; 21(3): 167-172.

Akhgari M, Amini-Shirazi N, Iravani FS: Forensic toxicology perspectives of methadone-associated deaths in Tehran, Iran, a 7-year overview. Basic Clin Pharmacol Toxicol. 2018; 122(4): 436-441.

Noori R, Narenjiha H, Aghabakhshi H, et al.: Methadone maintenance therapy outcomes in Iran. Subst Use Misuse. 2012; 47(7): 767-773.

Moradi G, Farnia M, Shokoohi M, et al.: Methadone maintenance treatment program in prisons from the perspective of medical and non-medical prison staff: A qualitative study in Iran. Int J Health Policy Manag. 2015; 4(9): 583-589.

Jabbehdari S, Farnaghi F, Shariatmadari SF, et al.: Accidental children poisoning with methadone: An Iranian pediatric sectional study. Iran J Child Neurol. 2013; 7(4): 32.

Bazmamoun H, Fayyaz A, Khajeh A, et al.: A study of methadone-poisoned children referred to Hamadan’s Besat Hospital/Iran. Iran J Child Neurol. 2014; 8(2): 34.

Taheri F, Yaraghi A, Sabzghabaee AM, et al.: Methadone toxicity in a poisoning referral center. J Res Pharm Pract. 2013; 2(3): 130-134.

Caplehorn JR, Drummer OH: Fatal methadone toxicity: Signs and circumstances, and the role of benzodiazepines. Aust N Z J Public Health. 2002; 26(4): 358-362.

Alinejad S, Kazemi T, Zamani N, et al.: A systematic review of the cardiotoxicity of methadone. EXCLI J. 2015; 14: 577.

Rostam-Abadi Y, Gholami J, Noroozi A, et al.: Public health risks associated with methadone in Iran: A systematic review and meta-analysis. Int J Drug Policy. 2022; 100: 103529.

Shokoohi M, Baneshi MR, Haghdoost A-A: Size estimation of groups at high risk of HIV/AIDS using network scale up in Kerman, Iran. Int J Prevent Med. 2012; 3(7): 471.

Fingerhut LA: Increases in poisoning and methadone-related deaths in United States, 1999-2005. National Center for Health Statistics Data Brief. 2008; 24: 1-8.

Aldabergenov D, Reynolds L, Scott J, et al.: Methadone and buprenorphine-related deaths among people prescribed and not prescribed opioid agonist therapy during the COVID-19 pandemic in England. Int J Drug Policy. 2022; 110: 103877.

Welsh C, Doyon S, Hart K: Methadone exposures reported to poison control centers in the United States following the COVID-19-related loosening of federal methadone regulations. Int J Drug Policy. 2022; 102: 103591.

Rege SV, Ngo DA, Ait-Daoud N, et al.: Epidemiology of pediatric buprenorphine and methadone exposures reported to the poison centers. Ann Epidemiol. 2020; 42: 50-57.e2.

Mohammadi N, Rastgoo N, Zadeh SE: Epidemiological and clinical features of acute poisoning in children in a referral teaching hospital in Iran, 2015-2018. J Compr Pediatr. 2020; 11(4): 219-225.

Ghaffourian T, Barati L, Khajavi A, et al.: Evaluation of methadone poisoning in pediatric emergency department, Gorgan, North of Iran (2011-19). J Gorgan Univ Med Sci. 2021; 23(4): 95-98.

Zamani N, Sanaei-Zadeh H, Mostafazadeh B: Hallmarks of opium poisoning in infants and toddlers. Trop Doct. 2010; 40(4): 220-222.

Abdoli H, Sadeghi T, Kazemi M: The effect of educating the clients of rehab centers on the frequency of methadone poisoning among children: A study from Iran. Int J Adolesc Med Health. 2020; 32(4): 20170189.

Ahmadi Forg F, Nasrabadi T, Alaee Karahroudy F: The effect of education on the prevention of children's poisoning with methadone on the awareness of mothers treated with methadone. Med Sci. 2022; 32(3): 328-336.

Alikhani B, Soleymanpour A, Sabzghabaee AM, et al.: Demographic, clinical, and forensics findings in deceased cases of acute methadone poisoning. J Isfahan Med School. 2017; 35(449): 1343-1351.

Astaraki P, Ahadi M, Salehinejad F, et al.: Fatalities due to poisoning with aluminum phosphide (rice pill) and methadone. Drug Res (Stuttg). 2022; 72(02): 82-85.

Lyons S: Risk of drug-related poisoning deaths and all-cause mortality among people who use methadone. Drugnet Ireland. 2020; 72: 22-24.

Shokrzadeh M, Yazdani CJ, Pourhossein M: Epidemiological study of mortality rate from opioid abuse in referential bodies to Mazandaran Department of Forensic Medicine. J Mazandaran Univ Med Sci. 2014; 24(115): 122-127.

Behnoush B, Taghadosinejad F, Salahshour B: Methadone overdose and its complications in patients admitted to the toxicology emergency ward of Baharloo Hospital of Tehran in 2011-2012. Iran J Toxicol. 2014; 7(23): 932-939.

Ghadirzadeh M, Yarinasab F, Amini K, et al.: Mortality rates due to substance and stimulants abuse in corpses submitted to the forensic medicine organization of Kohgiluyeh and Boyer-Ahmad province during 2013-2018. Iran J Forensic Med. 2019; 25(2): 145-150.

Zarghami M, Masoum B, Shiran M-R: Tramadol versus methadone for treatment of opiate withdrawal: A double-blind, randomized, clinical trial. J Addict Dis. 2012; 31(2): 112-117.

Shariatirad S, Maarefvand M, Ekhtiari H: Methamphetamine use and methadone maintenance treatment: An emerging problem in the drug addiction treatment network in Iran. Int J Drug Policy. 2013; 24(6): e115-e116.

Massah O, Moradi A: The prevalence of methamphetamine dependence among Iranian women in methadone maintenance therapy in Tehran, Iran. Iran J Psychiatry. 2018; 13(1): 10.